Study on Efficacy and Safety of Low-Dose Apatinib Combined with Camrelizumab and SOX Regimen as First-Line Treatment of Locally Advanced and Unresectable Gastric/Gastroesophageal Junction Cancer: A Protocol for an Open-Label, Dose Escalation and Extension Phase Ib Clinical Trial

BACKGROUND: The standard treatment for advanced gastric/gastroesophageal junction cancer (AGC/GEJC) is palliative chemotherapy combined with targeted therapy. The SOX regimen (S-1 plus oxaliplatin) is recommended as neoadjuvant or palliative first-line chemotherapy in Asian patients. Apatinib, an or...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Kang-Xin, Cui, Ting-Yun, Yang, Xu-Dong, Wang, Guo-Qun, Jiang, Qiu-Sheng, Sun, Hui, Jiang, Nan-Yuan, Yong, Xiao-Min, Shi, Chuan-Bing, Ding, Yong-Bin, Chen, Xiao-Feng, Fang, Yue-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464364/
https://www.ncbi.nlm.nih.gov/pubmed/34584426
http://dx.doi.org/10.2147/OTT.S316288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464364/
https://www.ncbi.nlm.nih.gov/pubmed/34584426
http://dx.doi.org/10.2147/OTT.S316288

Ejemplares similares